www.nature.com/onc

## **ORIGINAL ARTICLE** Established and new mouse models reveal E2f1 and Cdk2 dependency of retinoblastoma, and expose effective strategies to block tumor initiation

M Sangwan<sup>1</sup>, SR McCurdy<sup>1</sup>, I Livne-bar<sup>1</sup>, M Ahmad<sup>1</sup>, JL Wrana<sup>2</sup>, D Chen<sup>1</sup> and R Bremner<sup>1</sup>

 $RB^{+/-}$  individuals develop retinoblastoma and, subsequently, many other tumors. The Rb relatives p107 and p130 protect the tumor-resistant  $Rb^{-/-}$  mouse retina. Determining the mechanism underlying this tumor suppressor function may expose novel strategies to block Rb pathway cancers. p107/p130 are best known as E2f inhibitors, but here we implicate E2f-independent Cdk2 inhibition as the critical p107 tumor suppressor function *in vivo*. Like *p107* loss, deleting *p27* or inactivating its Cdk inhibitor (CKI) function ( $p27^{CK-}$ ) cooperated with *Rb* loss to induce retinoblastoma. Genetically, p107 behaved like a CKI because inactivating *Rb* and one allele each of *p27* and *p107* was tumorigenic. Although *Rb* loss induced canonical E2f targets, unexpectedly *p107* loss did not further induce these genes, but instead caused post-transcriptional Skp2 induction and Cdk2 activation. Strikingly, Cdk2 activity correlated with tumor penetrance across all the retinoblastoma models. Therefore, Rb restrains E2f, but p107 inhibits cross talk to Cdk. While removing either *E2f2* or *E2f3* genes had little effect, removing only one *E2f1* allele blocked tumorigenesis. More importantly, exposing retinoblastoma-prone fetuses to small molecule inhibitors of E2f (HLM006474) or Cdk (R547) for merely 1 week dramatically inhibited subsequent tumorigenesis in adult mice. Protection was achieved without disrupting normal proliferation. Thus, exquisite sensitivity of the cell-of-origin to E2f and Cdk activity can be exploited to prevent Rb pathway-induced cancer *in vivo* without perturbing normal cell division. These data suggest that E2f inhibitors, never before tested *in vivo*, or CKIs, largely disappointing as therapeutics, may be effective preventive agents.

Oncogene (2012) 31, 5019-5028; doi:10.1038/onc.2011.654; published online 30 January 2012

Keywords: chemoprevention; retinoblastoma; Cdk; E2f; p107

#### INTRODUCTION

The Rb-E2f and Cdk inhibitor (CKI)-Cdk2/1 interactions regulate cell cycle progression (Figure 1A). The Rb family (Rb, p107 and p130) bind and form repressor complexes with E2f family proteins. Activating E2fs, (E2f1/2/3) induce factors required for DNA replication, drive proliferation of quiescent cells (reviewed in Cobrinik<sup>1</sup> and Dimova and Dyson<sup>2</sup>) and, although not required for normal progenitor division,<sup>3</sup> are essential for abnormal division of differentiating *Rb*-null cells.<sup>4-8</sup> Cip/Kip inhibitors (p21/p27/p57) on the other hand bind and inhibit the kinase activity of Cyclin A/E-Cdk2/1 complexes. Cdk2 fires replication origins, and feeds back to promote E2f activity by phosphorylating Rb family proteins.<sup>9</sup>

To prevent uncontrolled G1-S progression, there are extensive controls limiting the positive cross talk between E2f and Cdk2 (Figure 1A). For example, by preventing Rb family phosphorylation, CKIs inhibit Cdk2-mediated activation of E2f. Equally, by preventing Cyclin E/A gene induction, the Rb family blocks E2f-mediated activation of Cdk2. Some work has emerged suggesting E2f-independent ways in which Rb proteins limit Cdk2 activity. For example, Rb promotes Skp2 degradation through APC and thus stabilizes CKIs.<sup>10,11</sup> Subsequent studies validated this link, as Skp2 is required in Rb-deficient pituitary tumors.<sup>12</sup> p107/p130 do not bind APC, but p107 reduces Skp2 post-transcriptionally *in vitro*;<sup>13</sup> whether this occurs *in vivo* is unclear. p107/p130 bind and inhibit

Cdk2 *in vitro*,<sup>14</sup> but a p107-Cdk2 complex in cells has only been detected in the absence of p21 and p27.<sup>15</sup> Thus, the extent to which p107 may utilize E2f-independent mechanisms to regulate Cdk2 *in vivo* and its relevance, if any, to tumorigenesis is unclear.

The ocular cancer retinoblastoma generated fundamental discoveries with broad relevance to cell cycle regulation and cancer, including the classic two-hit hypothesis and RB, the first recognized tumor suppressor. RB protein turned out to have universal relevance to cancer, and 50% of  $RB^{+/-}$  survivors develop secondary tumors by the age of 50 (reviewed in Balmer et al.<sup>16</sup>). The unique sensitivity of the human retina to RB loss implies that other human tissues and the retina in other species have extra protection. Indeed, p107 and p130 protect the mouse retina, and current retinoblastoma models utilize the loss of Rb and one relative.<sup>17-21</sup> How *p107/p130* protect the *Rb<sup>-/-</sup>* retina is unclear, but elucidating the mechanism could expose strategies to prevent tumors initiated by RB pathway defects in humans. One explanation for the quantum difference between the tumorresistant  $Rb^{-/-}$  and tumor-prone Rb/p107-null retina is that the E2f targets become super-induced in the latter. This occurs in keratinocytes,<sup>22,23</sup> but in fibroblasts Rb and p107/p130 appear to regulate distinct targets.<sup>24,25</sup> Here, we show that the major function of p107 in the Rb-null retina is not to regulate canonical

<sup>&</sup>lt;sup>1</sup>Toronto Western Research Institute, University Health Network, Departments of Ophthalmology and Visual Science, and Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada and <sup>2</sup>Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada. Correspondence: Dr R Bremner or Dr D Chen, Toronto Western Research Institute, University Health Network, Departments of Ophthalmology and Visual Science, and Laboratory Medicine and Pathobiology, University of Toronto, Room Mc6-424, 399 Bathurst Street, Toronto, Ontario, Canada M5T 2S8. E-mail: rbremner@uhnres.utoronto.ca or dchen@uhnres.utoronto.ca

Received 28 August 2011; revised 8 December 2011; accepted 22 December 2011; published online 30 January 2012



**Figure 1.** Both Rb-E2f and CKI-Cdk axes contribute to retinoblastoma initiation. (**A**) The Rb-E2f (red) and Cip/Kip-Cdk2 (green) dual axes regulate G1/S progression. There are also links that affect cross talk between the axes (blue). p107 is thought to inhibit cross talk by regulating E2f targets, but *in vitro* data also suggest E2f-independent roles in controlling Skp2 stability and in binding Cdk2 (dotted blue lines). The relative contribution of these pathways to p107 function *in vivo*, especially to tumor suppression, is unclear. The figure does not include all regulators and links. (**B**) Loss of *Rb* together with inactivation of *p107* and/or *p27*, either by deletion or by inactivating the latter's CKI activity, initiates the growth of protruding retinoblastoma (a-e) that fills the vitreous (f-j). H&E sections showed rosettes (k-t). Ki67 staining (u-y, green) reveals many dividing cells in tumors. For simplicity '*Rb*<sup>-/-</sup>' represents  $\alpha$ *Cre;Rb*<sup>f/f</sup>. Scale bars are 500 µm (f-j), 150 µm (k-o), 50 µm (p-t) and 25 µm (u-y).

E2f-regulated genes. Genetic, biochemical and pharmacological studies instead show that p107 prevents E2f-independent cross talk to Cdk2 and that combined activation of E2f and Cdk2, through loss of *Rb*, and *p107* or *p27*, respectively, underpins tumor susceptibility in the mouse retina. Strikingly, exposure of the fetal retina to either E2f or Cdk small molecule inhibitors for merely 1

week blocked retinoblastoma without perturbing normal division. We suggest that the sensitivity of the human retina to *RB* loss not only reflects E2F activation but also poor buffering of feedback regulation of CDKs. Given the universal role of the RB pathway in cancer, further studies are needed to assess the potential clinical relevance of our findings to multiple cancers.

#### RESULTS

#### CKI activity suppresses mouse retinoblastoma

Current mouse knockout models of retinoblastoma require the deletion of *Rb* plus either *p107* or *p130*.<sup>17-21</sup> p107 or p130 could protect  $Rb^{-/-}$  retina by repressing E2f targets, but we wondered if

Table 1. Tumor penetrance in <i>Rb</i> -null retinas with compromised p107 and/or CKI status				
p107 or p27 status of Rb-null retina	Eyes with tumor/total eyes	Penetrance (%)		
p107 <sup>-/-</sup>	12/22	54		
p107 <sup>+/-</sup>	0/60	0		
p27 <sup>-/-</sup>	28/28	100		
p27 <sup>+/-</sup>	0/24	0		
p27 <sup>CK-/CK-</sup>	20/20	100		
p27 <sup>+/CK-</sup>	3/28 (3/3 LOH)	10.7 (all LOH)		
p107 <sup>+/-</sup> ;p27 <sup>+/-</sup>	10/28 (0/5 LOH)	35.7 (no LOH)		
p107 <sup>+/-</sup> ;p27 <sup>+/CK-</sup>	7/18 (1/7 LOH)	38.9 (14% LOH)		
Abbreviations: CKL Cdk in	hibitor: LOH, loss of hetero	zvaosity. See also		

Supplementary Figure S3.



cross talk to Cdk may also be important (Figure 1A). When we deleted floxed Rb (Rb<sup>f</sup>) in peripheral retina at embryonic day 10 (E10) using the  $\alpha Cre$  transgene as before,<sup>5,18</sup> we observed elevated p21 and p27 mRNAs, with p27 protein detected in virtually all cells at postnatal day 8 (P8), and sporadic p21 expression (Supplementary Figure S1 and data not shown). To test whether CKI loss mimics p107 or p130 loss, we therefore removed p27. Strikingly,  $\alpha Cre; Rb^{f/f}p27^{-/-}$  mice developed retinoblastoma with 100% penetrance (Figure 1B and Table 1), double that of  $\alpha Cre; Rb^{f/f}p107^{-/-}$  mice and similar to  $\alpha Cre;Rb^{f/f}p130^{-/-}$  mice.<sup>18,19</sup> As in other double knockout models of retinoblastoma,<sup>17-21</sup> *Rb/p27* double knockout tumor cells expressed the amacrine cell marker Ap2a, as well as markers in this and other cells such as Pax6, and Prox1, but lacked other cell type markers (Figure 2 and Supplementary Figure S2). P30 tumor cells were positive for markers that label all cell cycle phases tumor cells were positive for markers that label all cell cycle phases (Ki67), or S-phase (BrdU). In  $Rb^{-/-};p107^{-/-}$ ,  $Rb^{-/-};p27^{-/-}$ ,  $Rb^{-/-};p27^{-/-}$ ,  $Rb^{-/-};p107^{+/-};p27^{+/--}$  and  $Rb^{-/-};p107^{+/-};p27^{+/CK^-}$  tumors, the fraction of Ki67<sup>+</sup> cells that were also Ap2 $\alpha^+$ was 92  $\pm$  4%, 91  $\pm$  1%, 92  $\pm$  5%, 92  $\pm$  2% and 90  $\pm$  1%, respectively, and the fraction of  $BrdU^+$  cells that were  $Ap2\alpha^+$ was  $89 \pm 11\%$ ,  $91 \pm 10\%$ ,  $85 \pm 4\%$ ,  $84 \pm 5\%$  and  $87 \pm 4\%$ , respectively (Figures 2b and c). The contaminating glutamine synthase-labelled Müller glia were quiescent (Supplementary Figure S2). Thus, in the



**Figure 2.** Dividing  $Ap2\alpha^+$  amacrine-like cells in multiple mouse models of retinoblastoma. (a) Tumors of the indicated genotypes and ages were stained for  $Ap2\alpha$  (green) and DAPI (blue). Scale bar = 100 µm. (b, c) Tumors of the indicated genotypes and ages were stained for the cell cycle markers Ki67 (b) and BrdU (c) (red), and the amacrine cell marker  $Ap2\alpha$  (green). White arrows indicate double positive cells. Scale bar = 20 µm. For simplicity ' $Rb^{-/-}$ ' represents  $\alpha Cre; Rb^{ff}$ . See also Supplementary Figure S2.

5022

 $Rb^{-/-}$  mouse retina, p27 is a potent tumor suppressor suggesting that low CKI activity in the human retina may contribute to the sensitivity of this tissue to *RB* loss.

p27 binds and regulates proteins other than Cyclin/Cdk2 (reviewed in Chu *et al.*<sup>26</sup>). To define the critical tumor suppressor activity, we assessed the  $p27^{CK-}$  allele in which four substitutions specifically disrupt CKI activity.<sup>27</sup>  $\alpha$ Cre;*Rb*<sup>6/f</sup> $p27^{CK-/CK-}$  mice developed retinoblastoma with 100% penetrance (Figure 1B and Table 1).  $p27^{CK-/CK-}$  animals exhibit retinal dysplasia,<sup>27</sup> which we confirmed, but they never developed retinoblastoma (data not shown). Furthermore, of the 28 eyes from  $\alpha$ Cre;*Rb*<sup>6/f</sup> $p27^{+/CK-}$  animals only 3 had tumors, and strikingly all showed loss of heterozygosity (Table 1 and Supplementary Figure S3). Thus,  $p27^{CK-}$  is not a dominant oncoprotein either in normal or  $Rb^{-/-}$  retina, contrasting lung where it causes tumors.<sup>27</sup> Collectively, our results demonstrate that retinoblastoma requires loss of p27 CKI activity.

These data suggest a role for Cdk in retinoblastoma initiation. Conceivably, p107 could, like p27, suppress tumorigenesis by limiting Cdk activity. To test this model, we first searched for genetic interaction between *p107* and *p27*. In stark contrast to  $\alpha Cre; Rb^{f/f} p107^{+/-}$  or  $\alpha Cre; Rb^{f/f} p27^{+/-}$  mice, which never developed retinoblastoma,  $\alpha Cre; Rb^{f/f} p107^{+/-}; p27^{+/-}$  compound heterozygotes developed tumors (Figure 1B, Table 1). Importantly, none of the five tumors analyzed showed loss of heterozygosity for *p107* or *p27* (Supplementary Figure S3 and data not shown). We also analyzed compound heterozygotes harboring the *p27<sup>CK-</sup>* allele ( $\alpha Cre; Rb^{f/f} p107^{+/-}; p27^{+/CK^-}$ ) and similarly observed retinoblastoma with only 1/7 tumors displaying loss of heterozygosity (Figure 1B, Table 1, Supplementary Figure S3C and data not shown). Previously, the Rb–E2f axis has been the focus in retinoblastoma, but these genetic data expose a new role for the CKI–Cdk axis.

#### Cdk2 activity correlates with tumor penetrance

Ouantifying tumor penetrance revealed various tumor frequencies across genetic models (Table 1). This variability might reflect differences in the activity of E2fs and/or Cdks. Normal retinal progenitor division, which is unaffected by Rb loss, ceases at post natal day 8 (P8), but ectopic division of differentiating *Rb*-null neurons continues.<sup>18,19</sup> Thus, E2f targets and Cdk activity were assessed at P8 to focus specifically on ectopically dividing differentiating cells. We assessed 24 E2f targets most of which were elevated in  $Rb^{-/-}$  retinas (Figure 3a). Surprisingly, in four tumor-prone genetic models, expression of these targets was remarkably similar to  $Rb^{-/-}$  levels (Figure 3a). We next analyzed Cdk pathway activity and found that Cdk2 protein was negligible in wild type (WT) retina, but induced similarly in  $Rb^{-\prime}$ and all tumor-prone models (Figure 3b). Strikingly, Cdk activity was strongly elevated in the tumor-prone state relative to Rb-null tumor-resistant retinas, and quantification revealed an excellent correlation with tumor penetrance (Figures 3b and c). However, we did not observe any correlation between Cdk2 kinase activity and cell cycle index (Supplementary Figure S4), excluding the possibility that higher Cdk activity is a result of increased cell proliferation in tumor-prone genotypes. Thus, while E2f is deregulated similarly in the tumorresistant Rb knock out (KO) versus tumor-prone states, Cdk2 activity predicts the susceptibility to sporadic transformation. This result, together with our new models of retinoblastoma, suggested that rather than constraining E2f target induction, p107 may protect the  $Rb^{-/-}$  retina by blocking cross talk to Cdk2.

#### p107 affects Skp2 and p27 levels in vivo

Typically, p107 is thought to influence Cdk activity through E2f regulation of Cyclins. However, as noted above, Cyclin A/E mRNA

induction was already maximal after Rb loss (Figure 3a). Cyclin E protein also showed similar or lower levels in tumor-prone retinas (Figure 4a). In vitro data link p107 to Cdk either directly by binding and inhibiting Cdk2,<sup>14</sup> or indirectly by decreasing Skp2 the substrate binding component of the SCF<sup>Skp2</sup> E3 ubiquitin ligase, which stimulates p27 degradation (Figure 1A).<sup>13</sup> Cdk2 was complexed with p21 and p27 in genotypes expressing these CKIs. However, no interactions were observed between Cdk2 and p107 or p130, arguing against a direct CKI function in vivo (Figure 4a). These results are consistent with in vitro data showing that p107 only binds CyclinA-Cdk2 in MEFs lacking both p21 and p27.15 p57 was also not detected in Cdk2 immunoprecipitates (IPs), and as expected p27 and p27<sup>CK-</sup> were not associated with Cdk2 in the  $Rb^{-/-};p27^{-/-}$  or  $Rb^{-/-};p27^{CK-/CK-}$  retina, respectively (Figure 4a). However, p27 bound Cdk2 in the  $Rb^{-/-}$ tumor-free retina and, consistent with a role in tumor suppression, the amount was reduced in tumor-prone  $Rb^{-/-}$ ;  $p107^{-/-}$  and  $Rb^{-/-}$ ; $p107^{+/-}$ ;  $p27^{+/-}$  retinas (Figure 4a). In  $Rb^{-/-}$ ;  $p107^{-/-}$  retina, the total amount of p27 was reduced by  $26 \pm 4\%$ , and the amount bound to Cdk2 was reduced by  $52 \pm 7\%$ , suggesting negative effects of p107 loss on both the level and function of this CKI. The level of p27-Cdk2 complexes across multiple models correlated inversely with both Cdk2 activity and tumor penetrance (Figures 4b and c). In addition, Skp2 showed increased protein levels when p107 was reduced or absent, suggesting that the p107-Skp2-p27 pathway described *in vitro* may be relevant *in vivo* (Figure 1A).<sup>13</sup> Skp2 induction was post-transcriptional as Skp2 mRNA levels were similar in tumor-resistant  $Rb^{-/-}$  retina versus tumor-prone retinas (Figure 3a). Total p21 levels were negligible in WT retina, low in  $Rb^{-/-}$  and  $Rb^{-/-}$ ;  $p107^{+/-}$ ;  $p27^{+/-}$  retinas, and induced in  $Rb^{-/-}$ ;  $p107^{-/-}$ ,  $Rb^{-/-}$ ;  $p27^{-/-}$  or  $Rb^{-/-}$ ;  $p27^{CK-/CK-}$  retina (Figure 4a). p21 associated with Cdk2 in five genotypes (Figure 4a). Unlike p27, p21 levels rose with increasing Cdk2 activity, although this positive correlation was poor (Supplementary Figure S5). Thus, p27 is the major CKI tumor suppressor in the  $Rb^{-/-}$  retina, and when it is missing  $(p27^{-/-})$ , unable to bind Cdk2  $(p27^{CK-/CK-})$  or reduced  $(p107^{-/-})$ , p21 is induced, but at insufficient levels to compensate for p27. Altogether, our data suggest that in *Rb/p107* mutant retinas Rb loss enhances E2f activity, whereas p107 loss elevates Skp2, reduces p27 and elevates Cdk2 activity, yielding the tumor-prone state.

#### Inhibiting either of the dual axes blocks tumorigenesis

Our results suggest that E2f and Cdk2 form dual axes that can generate three states: WT, ectopically dividing (Rb null) and tumorprone (Rb + p107 or p27-depleted), with only the latter being exquisitely dependent on the elevated activity of both axes. These findings led us to hypothesize that lowering the activity of either axis could prevent sporadic retinoblastoma arising from cancerprone cells. Removing E2f2 or E2f3 did not block retinoblastoma (Figure 5a, Table 2), concurring with the prior observation that E2f1, but not E2f2 or E2f3, drives ectopic division of differentiating neurons in the  $Rb^{-/-}$  retina.<sup>5</sup> p107 and E2f1 genes are in close proximity, hence to study E2f1 function in Rb/p107 double knockout retina, we screened >150 pups to isolate a crossover event generating linked *p107* and *E2f1*-null alleles. Although tumors occur in 54 or 100% of  $\alpha Cre;Rb^{f/f}p107^{-/-}$  or  $\alpha Cre;Rb^{f/f}p27^{-/-}$ retinas, respectively (Table 1), homozygous deletion of E2f1 completely blocked tumorigenesis in both models (Table 2). Notably, even reduction to heterozygosity completely blocked retinoblastoma in the  $\alpha Cre; Rb^{f/f}p107^{-/-}$  retina, and reduced penetrance from 100 to 10% in the  $\alpha Cre; Rb^{f/f}p27^{-/-}$  retina (Figure 5a, Table 2). Therefore, unlike normal cells, which proliferate in the absence of E2f1-3,<sup>3,4</sup> the tumor-prone state requires full E2f1 activity. Moreover, E2f1 heterozygosity did not affect progenitor division, but specifically reduced ectopic division



**Figure 3.** Cdk activity correlates with tumor penetrance. (a) Reverse transcription-qPCR was used to measure the mRNA level of the indicated E2f target genes in P8 retinas of the indicated genotypes. Heat map shows the  $\log_2$ -fold changes of gene expression relative to WT. Red and green colors represent positive and negative expression changes, respectively. E2f4 and 5 are not known E2f targets, but are included to show expression of the entire E2f family. (b) Cdk2 was immunoprecipitated from P8 retinas of the indicated genotypes. Kinase activity was determined using histone H1 as a substrate and the amount of Cdk2 in the IP was determined by western blotting. (c) Cdk activity (percent of that in the *Rb*-null retina) was plotted against tumor penetrance. *P* value was determined using a one-sample *t*-test for Pearson's product-moment correlational coefficient, *r*. All assays were carried out three to six times and the mean  $\pm$  s.d. is shown. For simplicity '*Rb*<sup>-/-</sup>' represents  $\alpha Cre; Rb^{f/f}$ .

in *Rb/p107*-deficient cells (Figures 5a and b). Thus, a therapeutic window of E2f activity exists that can be exploited to prevent abnormal pre-cancerous events without perturbing normal division.

Next, we examined whether lowering Cdk activity might also inhibit retinoblastoma initiation. Cdk1 can functionally substitute for Cdk2 *in vivo*,<sup>28</sup> thus we exploited a pharmaceutical approach to inhibit both and to test a novel chemoprevention strategy. Newborn neurons that survive *Rb/p107* loss divide ectopically, but the vast majority (millions) of neurons escape tumorigenesis by eventually exiting the cell cycle.<sup>18</sup> We hypothesized that– assuming drug crossed the placental barrier–mild and brief Cdk2 inhibition during this dangerous period of ectopic division would reduce sporadic transformation (Figure 6a). In contrast, if elevated Cdk activity is required only after transformation, this chemoprevention strategy would fail. For these assays we utilized R547, a potent CKI that passed preclinical evaluation<sup>29</sup> and is in phase I trials for solid tumors.<sup>30</sup> It does not inhibit 113 other kinases, and requires >100 fold higher doses to inhibit Gsk3 $\alpha/\beta$  versus Cdk1/2.<sup>29</sup>  $\alpha$ Cre;Rb<sup>f/f</sup>p27<sup>-/-</sup> males were bred to  $\alpha$ Cre;Rb<sup>f/f</sup>p27<sup>+/-</sup> females and pregnant dams received daily intraperitonial injections of vehicle or R547 (20 mg/kg) from embryonic day 12.5 (E12.5) to parturition and tumors were assessed at P45. Of eight eyes examined in the treatment group, six were tumor free, and tumor volume in the affected eyes was considerably reduced, also consistent with reduced tumor frequency (Figure 6b). The failure to block all tumor formation may be because of some late stage amacrine cell birth that occurs in the far periphery up to ~P3, beyond the period of R547 exposure.

We also examined models of retinoblastoma involving p107 instead of p27 loss, and to test a lower dose of R547. In  $\alpha$ Cre;Rb<sup>-/-</sup>;  $p107^{-/-}$  mice, Rb knockout and tumorigenesis is limited to the



**Figure 4.** p27 bound to Cdk2 correlates inversely with kinase activity and tumor penetrance. (**a**) Anti-Cdk2 immunoprecipitates or straight lysates (input) from P8 retina of the indicated genotypes were immunoblotted for the proteins indicated on the left. Values below input blots represent protein expression as a percentage of *Rb* KO retina in a representative blot. (**b**, **c**) Average amount of p27 bound to Cdk2 from three independent experiments was plotted against Cdk2 kinase activity (from Figure 3) (**b**) or tumor penetrance (**c**). '*Rb*<sup>-/-'</sup> is used to indicate *aCre;Rb*<sup>ff</sup>. *P* values were calculated using a one-sample *t*-test for Pearson's product-moment correlational coefficient, *r*. All assays were run a minimum of three times.

periphery with 54% penetrance (Table 1),18 whereas in Chx10Cre;Rb<sup>f/f</sup>p107<sup>-/-</sup> mice, Cre is expressed across the entire retina, there is considerable dysplasia and tumors emerge in multiple locations with 100% penetrance.<sup>21</sup> This pattern was observed in P45 mice born to dams exposed to the vehicle (Figure 6c). However, following a brief exposure of fetuses to R547, two of the eight eyes in the resultant adult mice were tumor free and the remainder showed much reduced tumor volume, most noticeably in the central retina, again consistent with the idea that Cdk inhibition in the embryonic retina blocks transformation of early-mid-born amacrine cells (Figure 6c, bottom panel). An appealing aspect of reduced E2f1 gene dosage was that it blocked tumorigenesis without perturbing normal division (Figures 5a and b). We further examined Chx10Cre;Rb<sup>f/f</sup>p107<sup>-/-</sup> retinas at P0, before tumor formation, for effects on division and the extensive dysplasia in this model. Strikingly, R547 reduced dysplasia (Figure 6d) and also modestly reduced ectopic mitoses, but had no effect on progenitor mitoses that are distant or adjacent to phalloidin-marked apical membranes, respectively (Figure 6e), thus resembling the effect of lowered E2f activity (Table 2 and Figure 5). Thus, only 1 week of pharmacological Cdk antagonism in fetuses is sufficient to inhibit the subsequent appearance of retinoblastoma in either Rb/p107 or Rb/p27-null cells, without perturbing normal progenitor division.

These results encouraged us to intervene pharmacologically with the E2f axis. Four inhibitors have been described of which three are peptides<sup>31-33</sup> and one is a small molecule inhibitor (HLM006474, abbreviated here to 6474).<sup>34</sup> To our knowledge, none have been tested *in vivo*. Although all four drugs inhibit division *in vitro*, only 6474 was tested on tissue, stalling tumor growth in a 3D skin model.<sup>34</sup> Strikingly, short exposure of *Chx10Cre;Rb<sup>ff</sup>p107<sup>-/-</sup>* embryos to 6474 had a dramatic effect on

tumorigenesis (Figure 6c). Thus, modest and temporary pharmaceutical E2f inhibition blocks retinoblastoma initiation.

Collectively, our results reveal greater dependency on E2f and Cdk activity for transformation than for normal progenitor proliferation (Figure 6f), creating a convenient therapeutic window in the cell-of-origin that, when targeted, dramatically impedes the subsequent emergence of cancer cells (Figure 6g).

#### DISCUSSION

Cross talk to Cdk2 as the primary tumor suppressor function of p107

A simple explanation for p107 tumor suppressor function is that it replaces the E2f repressor role of Rb. However, we found that multiple E2f-regulated genes, including canonical targets, were expressed at similar levels in *Rb* and *Rb/p107*-null retina, contrasting the situation in keratinocytes.<sup>22,23</sup> We acknowledge that although deletion of p107 did not result in further induction of well known E2f target genes in Rb-null retina, we can not rule out the possibility that the tumor-promoting effects of p107 loss may be mediated by E2f targets other than those tested in Figure 3a. However, akin to our in vivo findings, E2f-responsive reporter vectors show comparable activity in Rb or Rb/p107-null MEFs.<sup>35</sup> Notably, Rb, but not p107/p130, inhibits E2f target expression during senescence,<sup>36</sup> again mimicking our findings in terminally differentiating retinal neurons. Potentially, p107 cannot affect E2f targets in some Rb-null contexts because it is not recruited to these genes,<sup>36</sup> it is redundant with p130,<sup>24</sup> there is feedback inhibition of E2f by Cdk2-mediated phosphorylation<sup>37,38</sup> and/or it is already sequestered in other complexes.<sup>3</sup>

In stark contrast to E2f, we observed a marked increase in Cdk2 activity in the tumor-prone *Rb/p107*-null retina relative to the



**Figure 5.** Heterozygosity for *E2f1* is sufficient to block retinoblastoma. (**a**) P0 and adult (P30-P60) retinal sections of the indicated genotypes were stained for mitotic cells (PH3, red) and nuclei (DAPI, blue), or H&E (lower panels). Apical mitoses (white arrows) represent normal progenitors whereas ectopic mitoses (red arrows) represent abnormally dividing differentiating neurons that are abundant in the *Rb/p107*-null retina, and reduced or virtually absent when one or two *E2f1* alleles are removed, respectively. Scale bar =  $50 \,\mu\text{m}$ . The lens or tumors in adult H&E sections are indicated. For quantification of tumor frequency see Table 2. (**b**) Quantification of mitoses in indicated genotypes. Data are mean ± s.d. and asterisks indicate significant difference from WT (\**P*<0.05, \*\**P*<0.01. Students *t*-test For simplicity '*Rb<sup>-/-/</sup>* represents  $\alpha$ Cre;*Rb<sup>f/f</sup>* in (**a**, **b**). GCL, ganglion cell layer; NBL, neuroblastic layer.

Table 2. Tumor frequency in retinas lacking <i>E2f</i> alleles				
Genotype	Age analyzed (months)	No. of tumors/ no. of eyes analyzed	Tumor penetrance (%)	
Rb <sup>-/-</sup> ;p107 <sup>-/-</sup>	4	26/48	54	
Rb <sup>-/-</sup> ;p107 <sup>-/-</sup> ;E2f1 <sup>+/-</sup>	4	0/24	0	
Rb <sup>-/-</sup> ;p107 <sup>-/-</sup> ;E2f1 <sup>-/-</sup>	2	0/28	0	
Rb <sup>-/-</sup> ;p107 <sup>-/-</sup> ;E2f2 <sup>-/-</sup>	4	22/48	46	
Rb <sup>-/-</sup> ;p107 <sup>-/-</sup> ;E2f3 <sup>-/-</sup>	4	4/8	50	
Rb <sup>-/-</sup> ;p27 <sup>-/-</sup>	2	24/24	100	
Rb <sup>-/-</sup> ;p27 <sup>-/-</sup> ;E2f1 <sup>+/-</sup>	4	2/20	10	
Rb <sup>-/-</sup> ;p27 <sup>-/-</sup> ;E2f1 <sup>-/-</sup>	2	0/6	0	

tumor-resistant  $Rb^{-/-}$  tissue. E2f induction of Cyclins did not explain elevated Cdk2 activity, but we observed post-transcriptional induction of Skp2 and reduced p27-Cdk2 binding that correlated with kinase activity and tumorigenesis. New retinoblastoma models developed here coupled with biochemical and pharmacological data, strongly support the notion that this cross talk to Cdk2 is central to tumorigenesis: (i) Like the *Rb/p107*-null tissue the *Rb/p27*-deficient retina developed retinoblastoma, and *p27* or *p27<sup>CK-</sup>* alleles behaved identically; (ii) Compound heterozygosity for *p107* and either *p27* or *p27<sup>CK-</sup>* cooperated with *Rb* loss to drive retinoblastoma; (iii) Cdk2 activity correlated with tumor penetrance across these multiple models and (iv) Short-term exposure to a CKI prevented tumorigenesis in Rb/p107 and Rb/p27-null retinas. The ability of Rb pathway and CKI defects to cooperate is well known, 40-42 and we now extend this pattern to the retina where the focus had been primarily on Rb-E2f regulation. Our data are the first to prove unequivocally that it is the CKI function of p27 that cooperates with Rb to block tumorigenesis. Most importantly, they suggest that the primary tumor suppressive function of p107 in an Rb-null tissue is to prevent the activation of Cdk2 by E2f-independent and possibly Skp2-dependent means. Indeed, Skp2 is essential for retinoblastoma in the *Rb/p107*-null retina (MS and RB, unpublished data). These data justify further examination of the mechanism by which p107 might regulate Skp2 and cross talk to Cdk2, and expose potent chemopreventive strategies for Rb pathway-initiated tumors. It is interesting to note that the kinetics and penetrance of tumorigenesis in the Rb/p27-null retina are similar to that observed in the Rb/p130-null retina as shown by Macpherson et al.<sup>19</sup> In theory, p27 loss could stimulate phosphorylation and inactivation of p130. However, we did not observe an increase in the slower migrating hyperphosphorylated form of p130 in the *Rb/p27*-null retina (Figure 4a). Further work would be required to comprehensively assess individual p130 phosphorylation sites. An alternate possibility is that p130 affects p27 levels, either through Skp2 or another mechanism. It would be interesting to assess Skp2 and p27 levels in the Rb/p130-null retina.

© 2012 Macmillan Publishers Limited



Chemoprevention of retinoblastoma

M Sangwan et al

**Figure 6.** Chemoprevention of retinoblastoma through brief Cdk or E2f inhibition. (a) Summary of chemoprevention strategy. (b) H&E stain of P45 retina in  $\alpha Cre;Rb^{f/f};p27^{-/-}$  mice treated with either vehicle (n = 8) or pan-CKI R547 (n = 10) with quantification of tumor volume (bottom panel). (c) H&E stain of P45 retina in  $Chx10Cre;Rb^{f/f};p107^{-/-}$  mice treated with vehicle (n = 10), R547 (n = 8) or E2f inhibitor HLM006474 (n = 4) with tumor volume quantified (lower panel). (b, c) T, tumor; R, retina; L, lens; ON, optic nerve (scale bar = 1 mm). (d) P0 retina of  $Chx10Cre;Rb^{f/f};p107^{-/-}$  mice treated with PH3 (green) and the F-actin marker, phalloidin (red). Yellow arrows indicate ectopic PH3<sup>+</sup> cells and white arrowheads represent apical mitotic progenitors (scale bar = 50 µm). (e) Quantification of ectopic (µper panel) or apical (lower panel) mitoses per section shows that the drug inhibits abnormal, but not normal division. \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.0001 compared with vehicle using an unpaired Student's t-test (b) or one-way analysis of variance followed by Bonferroni multiple comparisons posthoc test (c, f). Data represented as mean ± s.e.m. (*n* represented per eye,  $n \ge 4$  for each condition). (f) Model summarizing critical molecular steps to the tumor-prone state. In the mouse retina, Rb loss activates E2f1 and triggers ectopic division (red step), but additional genetic events are required to activate Cdk2 and thus create tumor susceptibility (yellow step). Sporadic mutations permit progression to cancer (green step). (g) The data suggest distinct dependence on E2f and Cdk activity for normal division, ectopic division and tumor susceptibility, and thus expose a therapeutic window of dual axes activity that can be exploited to block transformation.

A model to explain variable sensitivity to *RB* inactivation The human retina is exquisitely sensitive to *RB* defects, but the underlying reason is unclear. Our data show that p107 protects mouse retina by preventing cross-activation of Cdk2 and thus cooperation with elevated E2f to create tumor susceptibility. We suggest, therefore, that low or negligible p107/p130/CKIs levels or activity in the human retinoblastoma cell-of-origin strengthens positive feedback regulation between E2Fs and CDKs. *Rb* loss

alone in this case would be sufficient to raise Skp2 levels, reduce p27 further and thus efficiently activate Cdk2 (Figure 1A). Mouse pituitary shows the same sensitivity to *Rb* loss as the human retina,<sup>43</sup> suggesting it also has unusually higher level of E2F and CDK activity. Finally, although inducing E2f or Cdk activity drives temporary ectopic proliferation in *Drosophila*, extended abnormal division requires both.<sup>44</sup> Thus, a buffer that limits E2f to Cdk positive feedback regulation may be critical to avoid tumorigenesis in all animals.

#### Clinical relevance

Chemoprevention is a growing field with important successes.<sup>45</sup> Long-term exposure to anti-inflammatory drugs such as aspirin and non-steroidal anti-inflammatory drugs reduces cancer incidence, but failures, such as the lack of protection afforded by statins, highlight the need to define optimal targets.<sup>45</sup> The notion of prevention as a viable goal has gained considerable ground in recent years, in particular for familial cancers of which > 50 have been identified.<sup>46</sup> In addition, effective chemopreventative strategies could also benefit cancer survivors, who are at higher risk of secondary tumors.<sup>47</sup>

Here, we prevented cancer in an in vivo model of tumorigenesis using two distinct small molecule therapies, and with only 1 week of drug treatment. These striking observations have implicit clinical relevance, especially as they were obtained using genetic models that mimic human cancer, rather than cell-line derived xenografts in immunodeficient hosts. Our data raise the exciting notion that  $RB^{+/-}$  patients, who often die of secondary tumors, may benefit from the preventive therapy we show that is so potent in retina. Moreover, because the RB pathway is disrupted in many cancers, and elevated E2F and CDK activity is a universal feature of human tumors, our chemopreventive strategies may be broadly relevant. Although Cdk2 is dispensable for tumorigenesis in *p27*, *p21* or *p53*-null mice,<sup>49-51</sup> it acts redundantly with Cdk1,<sup>28</sup> thus the success of our chemotherapeutic strategy likely reflects the inhibition of both kinases. Our data provide the first successful application of any E2f inhibitor in vivo and the remarkable efficacy indicates that like Cdk, E2f is an important chemopreventative target, although further work is required to confirm if this inhibitor lowers E2F target levels in vivo. Therapeutic trials with Cdk2 inhibitors in human cancer have been largely unsuccessful,<sup>9</sup> but we suggest that their real benefit may lie in prevention. Recent work with CKIs in genetic models of colon cancer supports this notion.<sup>52</sup> Future studies should examine whether the cell-of-origin in this and other tumor types also require elevated E2f activity. We found that E2f or Cdk inhibition could prevent retinoblastoma without perturbing normal retinal progenitor cell division. These data indicate a unique role for E2f and Cdk in supporting transformation versus normal cell cycle progression.

#### Note added in proof

As we were preparing our manuscript for submission, David Macpherson's lab published work showing that microRNAs that downregulate the CKI p21 are amplified or overexpressed in mouse and human retinoblastoma.<sup>53</sup> These data support the notion that Rb and CKI inactivation cooperate to transform the human retina.

#### MATERIALS AND METHODS

#### Mouse strains and genotyping

Mice were treated according to institutional and national guidelines.  $\alpha$ Cre mice (P. Gruss), *Rb<sup>f/f</sup>* mice (A. Berns), *p107<sup>-/-</sup>* mice (M. Rudnicki), *p27<sup>-/-</sup>* mice (J. Roberts) and *p27<sup>Ck-/Ck-</sup>* mice (J. Roberts), were maintained on a mixed background. Different genotypes were compared within the same litter and across at least three litters. Genotyping was performed as before.<sup>18,27</sup>

#### Histology and immunofluorescence

BrdU-labelling, fixation and immunostaining were performed as before.<sup>3,5</sup> For p27, p21 and Ki67 antigen retrieval was performed by boiling sections in citric acid (H-3300, Vector Lab Inc., Burlington, ON, Canada).

#### RNA-extraction, reverse transcriptionc-PCR

Reverse transcription-qPCR for E2f targets were run in duplicate on at least three separate biological samples as described.<sup>3</sup>

#### Western blots

Mouse retinas were homogenized with a 30-gauge needle (BD Biosciences, Bedford, MA, USA) 5–10 times in lysis buffer. Proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membrane. Blots were blocked and probed as described.<sup>5</sup> Blots were scanned using ODYSSEY Infrared Imaging System (LI-COR, Lincoln, NE, USA).

#### Immunoprecipitation and kinase assays

Complete radio-immunoprecipitation assay (RIPA) buffer was prepared by combining phenylmethanesulfonylfluoride, sodium orthovanadate, protease inhibitor cocktail (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Mouse retinas were lysed in RIPA and pre-cleared with 1.0  $\mu$ g of rabbit IgG. Supernatant containing 250  $\mu$ g total protein was incubated with 1  $\mu$ g primary antibody at 4 °C for 2 h. 20  $\mu$ l of resuspended Protein A/G Plus-Agarose (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was added and rocked at 4 °C for 1 h to overnight. Kinase reactions were performed at 30 °C for 15 min in kinase buffer containing 2.5  $\mu$ g histone H1 (Upstate Biotechnology, Buffalo, NY, USA), 2  $\mu$ Ci of  $^{32}$ P- $\gamma$ -ATP and 20  $\mu$ M ATP. Reactions were stopped with 2 × Laemmli buffer and boiled for 5 min before loading on 10% SDS-polyacrylamide gel electrophoresis gels. Gels were dried and quantified using phosphoimager.

#### Chemoprevention

R547 and 6474 were synthesized by University Health Network Shanghai, and purity confirmed at > 98% according to published methods.<sup>29,34</sup> Male and female mice were mixed in the early afternoon, checked the following morning and dams with vaginal plugs considered to be 0.5 days post coitus (E0.5). After 12 days, pregnant dams were treated with either vehicle (2.5% vol/vol dimethylsulphoxide (5% for 20 mg/kg dose), 28% wt/vol 2-hydroxypropyl- $\beta$ -cyclodextrin, 10% vol/vol PEG400 in distilled water), or R547 (5-20 mg/kg) or 6474 (100 mg/kg) daily intraperitoneally until birth.

#### Tumor volume and stereology

Eyes were sectioned horizontally at  $14\,\mu$ m. Every eighth section was stained with hematoxylin and eosin (H&E) and scanned on Leica DMRB (Wetzlar, Germany). Tumor volume was estimated using a Cavalieri Estimator in Stereo Investigator (MBF Bioscience, San Diego, CA, USA).

#### Statistical analysis

Statistical analysis was performed using Prism software (Version 5.0a, GraphPad Software, LaJolla, CA, USA).

#### **CONFLICT OF INTEREST**

There is potential conflict of interest.

#### ACKNOWLEDGEMENTS

We thank Arnaud Besson and James Roberts for sharing  $p27^{CK-/CK-}$  mice, and Fred Dick, Gustavo Leone and Philippe Monnier for comments. This project was funded by grants to RB from the Canadian Institutes for Health Research (CIHR), Foundation Fighting Blindness Canada, Ontario Institute for Cancer Research through funding provided by the Government of Ontario and the Terry Fox Research Institute. MS, MA and SRM were supported in part by fellowships from a CIHR training program.



#### 5028 REFERENCES

- 1 Cobrinik D. Pocket proteins and cell cycle control. Oncogene 2005; 24: 2796-2809.
- 2 Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaintances with new faces. Oncogene 2005; 24: 2810-2826.
- 3 Chen D, Pacal M, Wenzel PL, Knoepfler PS, Leone G, Bremner R. Division and apoptosis of E2f-deficient retinal progenitors. *Nature* 2009; **462**: 925.
- 4 Chong JL, Wenzel PL, Saenz-Robles MT, Nair V, Ferrey A, Hagan JP *et al.* E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells. *Nature* 2009; **462**: 930-934.
- 5 Chen D, Opavsky R, Pacal M, Tanimoto N, Wenzel P, Seeliger MW et al. Rb-Mediated Neuronal Differentiation through Cell-Cycle-Independent Regulation of E2f3a. PLoS Biol 2007; 5: e179.
- 6 Tsai KY, Hu Y, Macleod KF, Crowley D, Yamasaki L, Jacks T. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. *Mol Cell* 1998; **2**: 293 304.
- 7 Ziebold U, Reza T, Caron A, Lees JA. E2F3 contributes both to the inappropriate proliferation and to the apoptosis arising in Rb mutant embryos. *Genes Dev* 2001; 15: 386-391.
- 8 McClellan KA, Ruzhynsky VA, Douda DN, Vanderluit JL, Ferguson KL, Chen D *et al.* Unique requirement for Rb/E2F3 in neuronal migration: evidence for cell cycleindependent functions. *Mol Cell Biol* 2007; 27: 4825 - 4843.
- 9 Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. *Nat Rev Cancer* 2009; **9**: 153-166.
- 10 Binne UK, Classon MK, Dick FA, Wei W, Rape M, Kaelin Jr WG et al. Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. Nat Cell Biol 2007; 9: 225 - 232.
- 11 Ji P, Jiang H, Rekhtman K, Bloom J, Ichetovkin M, Pagano M et al. An Rb-Skp2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partialpenetrance Rb mutant. *Mol Cell* 2004; **16**: 47-58.
- 12 Wang H, Bauzon F, Ji P, Xu X, Sun D, Locker J et al. Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice. Nat Genet 2010; 42: 83-88.
- 13 Rodier G, Makris C, Coulombe P, Scime A, Nakayama K, Nakayama KI et al. p107 inhibits G1 to S phase progression by down-regulating expression of the F-box protein Skp2. J Cell Biol 2005; 168: 55-66.
- 14 Castano E, Kleyner Y, Dynlacht BD. Dual cyclin-binding domains are required for p107 to function as a kinase inhibitor. *Mol Cell Biol* 1998; 18: 5380-5391.
- 15 Chibazakura T, McGrew SG, Cooper JA, Yoshikawa H, Roberts JM. Regulation of cyclin-dependent kinase activity during mitotic exit and maintenance of genome stability by p21, p27, and p107. *Proc Natl Acad Sci USA* 2004; **101**: 4465-4470.
- 16 Balmer A, Zografos L, Munier F. Diagnosis and current management of retinoblastoma. Oncogene 2006; 25: 5341-5349.
- 17 Robanus-Maandag E, Dekker M, van der Valk M, Carrozza ML, Jeanny JC, Dannenberg JH *et al.* p107 is a suppressor of retinoblastoma development in pRbdeficient mice. *Genes Dev* 1998; **12**: 1599-1609.
- 18 Chen D, Livne-Bar I, Vanderluit JL, Slack RS, Agochiya M, Bremner R. Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically death-resistant cell-of-origin in retinoblastoma. *Cancer Cell* 2004; 5: 539-551.
- 19 MacPherson D, Sage J, Kim T, Ho D, McLaughlin ME, Jacks T. Cell type-specific effects of Rb deletion in the murine retina. *Genes Dev* 2004; 18: 1681-1694.
- 20 Dannenberg JH, Schuijff L, Dekker M, van der Valk M, te Riele H. Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130. *Genes Dev* 2004; **18**: 2952 - 2962.
- 21 Zhang J, Schweers B, Dyer MA. The First Knockout Mouse Model of Retinoblastoma. *Cell Cycle* 2004; **3**: 952-959.
- 22 Lara MF, Garcia-Escudero R, Ruiz S, Santos M, Moral M, Martinez-Cruz AB *et al.* Gene profiling approaches help to define the specific functions of retinoblastoma family in epidermis. *Mol Carcinog* 2008; **47**: 209-221.
- 23 Lara MF, Santos M, Ruiz S, Segrelles C, Moral M, Martinez-Cruz AB et al. p107 acts as a tumor suppressor in pRb-deficient epidermis. Mol Carcinog 2008; 47: 105 - 113.
- 24 Hurford Jr RK, Cobrinik D, Lee MH, Dyson N. pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. *Genes Dev* 1997; **11**: 1447-1463.
- 25 Black EP, Huang E, Dressman H, Rempel R, Laakso N, Asa SL *et al.* Distinct gene expression phenotypes of cells lacking Rb and Rb family members. *Cancer Res* 2003; **63**: 3716-3723.
- 26 Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. *Nat Rev Cancer* 2008; 8: 253-267.
- 27 Besson A, Hwang HC, Cicero S, Donovan SL, Gurian-West M, Johnson D et al. Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. *Genes Dev* 2007; 21: 1731-1746.

- 28 Santamaria D, Barriere C, Cerqueira A, Hunt S, Tardy C, Newton K et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 2007; 448: 811-815.
- 29 DePinto W, Chu XJ, Yin X, Smith M, Packman K, Goelzer P et al. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. *Mol Cancer Ther* 2006; 5: 2644 - 2658.
- 30 Malumbres M, Pevarello P, Barbacid M, Bischoff JR. CDK inhibitors in cancer therapy: what is next? *Trends Pharmacol Sci* 2008; **29**: 16-21.
- 31 Bandara LR, Girling R, La Thangue NB. Apoptosis induced in mammalian cells by small peptides that functionally antagonize the Rb-regulated E2F transcription factor. *Nat Biotechnol* 1997; **15**: 896-901.
- 32 Fabbrizio E, Le Cam L, Polanowska J, Kaczorek M, Lamb N, Brent R *et al.* Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity. *Oncogene* 1999; **18**: 4357-4363.
- 33 Montigiani S, Muller R, Kontermann RE. Inhibition of cell proliferation and induction of apoptosis by novel tetravalent peptides inhibiting DNA binding of E2F. Oncogene 2003; 22: 4943 - 4952.
- 34 Ma Y, Kurtyka CA, Boyapalle S, Sung SS, Lawrence H, Guida W et al. A smallmolecule E2F inhibitor blocks growth in a melanoma culture model. *Cancer Res* 2008; 68: 6292-6299.
- 35 Classon M, Salama S, Gorka C, Mulloy R, Braun P, Harlow E. Combinatorial roles for pRB, p107, and p130 in E2F-mediated cell cycle control. *Proc Natl Acad Sci USA* 2000; **97**: 10820 - 10825.
- 36 Chicas A, Wang X, Zhang C, McCurrach M, Zhao Z, Mert O et al. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. *Cancer Cell* 2010; **17**: 376-387.
- 37 Xu M, Sheppard KA, Peng CY, Yee AS, Piwnica-Worms H. Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. *Mol Cell Biol* 1994; 14: 8420-8431.
- 38 Dynlacht BD, Flores O, Lees JA, Harlow E. Differential regulation of E2F transactivation by cyclin/cdk2 complexes. *Genes Dev* 1994; 8: 1772-1786.
- 39 Lee EY, Cam H, Ziebold U, Rayman JB, Lees JA, Dynlacht BD. E2F4 loss suppresses tumorigenesis in Rb mutant mice. *Cancer Cell* 2002; **2**: 463-472.
- 40 Brugarolas J, Bronson RT, Jacks T. p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells. J Cell Biol 1998; **141**: 503-514.
- 41 Park MS, Rosai J, Nguyen HT, Capodieci P, Cordon-Cardo C, Koff A. p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. *Proc Natl Acad Sci* USA 1999; **96**: 6382-6387.
- 42 Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S et al. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. *Genes Dev* 1998; **12**: 2899-2911.
- 43 Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. Effects of an *Rb* mutation in the mouse. *Nature* 1992; **359**: 295-300.
- 44 Buttitta LA, Katzaroff AJ, Perez CL, de la Cruz A, Edgar BA. A double-assurance mechanism controls cell cycle exit upon terminal differentiation in *Drosophila*. *Dev Cell* 2007; **12**: 631-643.
- 45 Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ *et al.* Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. *Clin Cancer Res* 2006; **12**: 3661–3697.
- 46 Lindor NM, McMaster ML, Lindor CJ, Greene MH. Concise handbook of familial cancer susceptibility syndromes - second edition. J Natl Cancer Inst Monogr 2008; 38: 1 - 93.
- 47 Ng AK, Kenney LB, Gilbert ES, Travis LB. Secondary malignancies across the age spectrum. Semin Radiat Oncol 2010; 20: 67-78.
- 48 Yu CL, Tucker MA, Abramson DH, Furukawa K, Seddon JM, Stovall M et al. Causespecific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst 2009; 101: 581-591.
- 49 Padmakumar VC, Aleem E, Berthet C, Hilton MB, Kaldis P. Cdk2 and Cdk4 activities are dispensable for tumorigenesis caused by the loss of p53. *Mol Cell Biol* 2009; 29: 2582–2593.
- 50 Martin A, Odajima J, Hunt SL, Dubus P, Ortega S, Malumbres M et al. Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell 2005; 7: 591-598.
- 51 Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. *Cancer Cell* 2003; **3**: 233-245.
- 52 Boquoi A, Chen T, Enders GH. Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032. *Cancer Prev Res (Phila)* 2009; **2**: 800-806.
- 53 Conkrite K, Sundby M, Mukai S, Thomson JM, Mu D, Hammond SM et al. miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma. Genes Dev 2011; 25: 1734-1745.

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)



Figure S1. Expression of p21 and p27 at P8 in WT and Rb null retina Real-time RT-PCR analysis of Cdkn1a (p21) and Cdkn1b (p27) genes in WT and Rb null retinas at P8. Error bar represent SD of measurements from three independent experiments.



# Figure S2. Emerging $Rb^{-/-}$ ; $p27^{-/-}$ tumors contain dividing cells positive for amacrine cell markers

(A) Marker analysis of P30 WT and  $Rb^{-/-};p27^{-/-}$  retina. Low magnification views are shown on the left (scale bar 100 µm) and high magnification views of the boxed regions are shown on the right (scale bar 20 µm). Emerging tumors stained primarily for Ap2a (green), which specifically marks amacrine cells, Pax6 (red), which marks amacrine cells as well as other cell types, and Ki67 (green) which marks dividing cells. Tumors had no or very few cells that stained for markers of cone (Cone arrestin), bipolar (Chx10), ganglion (Brn3b) or rod (Retp1) cells. All sections in A were also stained with DAPI to mark nuclei (blue).

(B) Tumors at P30 were labeled with Ki67 (green) to mark dividing cells, Prox1 (red) which marks horizontal, bipolar and a subset of amacrine cells in normal adult retina, and DAPI to label nuclei (blue).

(C)  $Prox1^+$  cells (red) were amacrine-like as they co-stained for Ap2a (green). Scale bar 100  $\mu m$  upper panel and 20  $\mu m$  lower panel.

(D) Tumors were stained for Ki67 and glutamine synthase (GS, green), which marks Müller glia. These cells, unlike those with amacrine markers were not dividing. Scale bar 20  $\mu$ m. In A-D, for simplicity "*Rb*-/-" represents  $\alpha$ *Cre;Rb*<sup>f/f</sup>.



### Figure S3. LOH analysis in heterozygotes

(A) Genotyping of tail (TI) and tumor (Tm) DNA for  $p27^{cK-}$  allele in  $\alpha Cre;Rb^{f/f};p27^{*/CK-}$  mice showing LOH as indicated by single 600 bp band for  $p27^{CK-}$  knock-in allele and loss of 520 bp band for WT allele in tumor DNA for all three tumor samples. The  $p27^{CK-}$  diagnostic primers also often generate a background band between the 600 bp and 520 bp fragments.

(B) Genotyping of four  $\alpha Cre; Rb^{f/f}; p107^{*/-}; p27^{*/-}$  mice showing no LOH for p27 (upper panel; WT allele 400 bp and KO allele 550 bp) and p107 (lower panel; WT allele 386 bp and KO allele 513 bp).

(C)  $\alpha Cre; Rb^{f/f}; p10\dot{7}^{*/-}; p27^{*/CK-}$  tumor showing LOH for  $p27^{CK-}$  knockin allele in only a single tumor sample (Tm4; upper panel) and no LOH for p107 allele (lower panel). \* Tumor samples showing LOH.



Figure S4. At P8 CDK2 activity does not correlate with cell cycle index (A) P8 retinas of the indicated genotypes were stained for Ki67 (green) and DAPI (blue). Scale bar 50  $\mu$ m. (B) Quantification Ki67 positive cells in indicated genotypes. Data are mean ± SD. (C) Cdk2 kinase activity (percent of that in the Rb null retina) was plotted against percentage of Ki67<sup>+</sup> cells at P8. p value was determined using a one-sample *t*-test for Pearson's product-moment correlational coefficient, r. All assays were carried out at least 3 times. For simplicity "Rb<sup>-/-</sup>" represents  $\alpha Cre; Rbf/f$ .



Figure S5. p21 levels bound to Cdk2 do not correlate with kinase activity Cdk2 kinase activity (from figure 3) was plotted against the amount of p21 bound to Cdk2. " $Rb^{-/-"}$  is used to indicate  $\alpha Cre; Rb^{f/f}$ . p values were calculated using a one-sample t-test for Pearson's product-moment correlational coefficient, r.